leadf
logo-loader
viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies wins US$75K grant from North Dakota to fund coronavirus treatments

In addition, the company was approved for a US$209,000 loan under the Payroll Protection Program

Person wearing medical mask and nursing cap holding a vial of blood labeled 'coronavirus'
ImmunoPrecise, which is focused on antibody discovery, will address both prophylactic and therapeutic measures to fight the virus and its associated disease, COVID-19.

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCQB:IPATF) has been awarded a US$75,000 grant from the state of North Dakota to fund its PolyTope mAb Therapy platform, which the company is using to developing treatments for the coronavirus (COVID-19) and other pathogens.

The grant is the first of several applications that ImmunoPrecise plans to submit over the next several months, the company said.

ImmunoPrecise, which is focused on antibody discovery, will address both prophylactic and therapeutic measures to fight the virus and its associated disease, COVID-19.

READ: ImmunoPrecise Antibodies says coronavirus research activities for experimental vaccines and therapeutics advancing

"ImmunoPrecise is in the process of applying for both state and federal grants to support the development of a treatment for COVID-19 using our PolyTope mAb Therapy," CEO Jennifer Bath said in a statement. "We turned first to the State of North Dakota, given their strong history of support for biotechnology and innovation. It is with gratitude we accept the ND Bioscience Innovation Grant and we are confident we can leverage this funding, along with our research advances, to continue to build on our current successes."

In addition, the company was approved for a US$209,000 loan under the Payroll Protection Program administered by the US Small Business Administration during the coronavirus pandemic. Immunoprecise qualified as a business with fewer than 500 employees.

The loan has a term of two years and will be forgiven if the company uses the funds to cover payroll costs over the next eight weeks, with 25% allowed for rent and utilities.

Lastly, ImmunoPrecise plans to complete a non-brokered private placement offering of 10% convertible debentures in the principal amount of C$2 million. The debentures are unsecured, bear interest at a rate of 10% per year, are payable annually and due after two years. 

The principal can be converted into units of the company at a conversion price of C$0.85 per share, although the company can force convert the principal if the average closing price is at or above C$1.50 for 20 trading days and it announces its intention to do so.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 2.5 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $174.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 2/4/19

2 min read